Skip to content
Screener

Insulet PODD Other Income (Expense)

Other Income (Expense) at other companies

Eli Lilly logo
Eli LillyLLY
$269M+399%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
-$6.87M-16.1%
Medtronic logo
MedtronicMDT
$137M
Beta Bionics logo
Beta BionicsBBNX
$2.18M-27.6%
Embecta Corp. logo
Embecta Corp.EMBC
-$2.9M-625%
Opko Health logo
Opko HealthOPK
-$6.43M+93.7%

Other financials

Income statement

See full
Revenue$801.7M+23.5%
Gross profit$562.6M+24.4%
Operating income$129.7M+7.1%
Net income$95.0M+322%
EPS (diluted)$1.37+328%

Balance sheet

See full
Cash & equivalents$534.9M-52.3%
Total debt$974.7M-47.6%
Total equity$1.4B-2.8%
Total assets$3.2B-8.8%

Cash flow

See full
Operating cash flow$88.4M-55.0%
CapEx$32.5M+74.7%
Free cash flow$55.9M-68.6%

Valuation

See full
Market cap$9.23B-52.7%
Enterprise value$9.67B-52.3%
P/E24.6×-58.1×
P/S-5.2×

Profitability

See full
Gross margin71.1%+0.3pp
Operating margin16.9%-0.4pp
Net margin12.3%+2.3pp
FCF margin9.6%-7.5pp

Returns & leverage

See full
Return on equity26%+6.8pp
Debt / equity0.7×-0.6×
Current ratio2.5×+0.2×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Insulet’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001145197-26-000169
(in millions, except share and per share data)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest expense(13.5)(19.6)(28.2)(28.8)
Interest income3.610.18.520.3
Loss on extinguishment of debt(84.4)(123.9)
Other (expense) income, net(1.1)1.3(0.4)(0.9)
Income before income taxes118.728.4231.776.5
Income tax expense(23.7)(5.9)(45.6)(18.6)
Net income$95.0$22.5$186.1$57.9
Earnings per share:

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Insulet's other income (expense)?
Insulet (PODD) reported other income (expense) of -$1.1M in Q2 2026.
How has Insulet's other income (expense) changed year-over-year?
Insulet's other income (expense) decreased by 184.6% year-over-year, from $1.3M to -$1.1M.
What is the long-term trend for Insulet's other income (expense)?
Over 3 years (2021 to 2025), Insulet's other income (expense) has grown at a 96.0% compound annual growth rate (CAGR), from -$1.9M to $14.3M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Insulet's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude